Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has received an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) is set to post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Travere Therapeutics to post earnings of ($0.98) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Travere Therapeutics (NASDAQ:TVTX […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price objective increased by HC Wainwright from $17.00 to $19.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 252.50% from the company’s current price. HC […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) shares were down 6% during trading on Monday . The company traded as low as $7.25 and last traded at $7.25. Approximately 249,563 shares were traded during trading, a decline of 80% from the average daily volume of 1,219,567 shares. The stock had previously closed at $7.71. […]